A survey on the relationship between serum 25-hydroxy vitamin D level and tumor characteristics in patients with breast cancer

Ghasem Janbabai¹, Ramin Shekarriz², Homa Hassanzadeh³, Mohsen Aarabi⁴, Seyyedeh Samaneh Borhani⁵

¹Associate Professor, Medical Oncologist-Hematologist, Gastrointestinal Cancer Research Center, Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran
²Assistant Professor, Medical Oncologist-Hematologist, Gastrointestinal Cancer Research Center, Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran
³Internist, Department of Internal Medicine, Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran
⁴Assistant Professor, Epidemiologist, Mazandaran University of Medical Sciences, Health Sciences Research Center, Sari, Iran
⁵General Physician, Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran

Corresponding Author: Ramin Shekarriz, MD. Assistant Professor, Medical Oncologist-Hematologist, Gastrointestinal Cancer Research Center, Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran
Tel: +989123061858
Fax: +981133374977
Email: drraminshekarriz@yahoo.com

ABSTRACT

Background: In recent years, epidemiologic and laboratory studies have implied that vitamin D deficiency has a role in the pathogenesis of breast cancer. It has shown that vitamin D can prevent tumor progression induced by carcinogens and inhibit the carcinogenic effects of high fat diet on breast tissue and growth of tumor cells. This study aimed to evaluate serum 25-hydroxyvitamin D level and its role in relation to tumor characteristics and different stages of disease in women with breast cancer.

Subject and Methods: This is a cross-sectional study on 200 patients with breast cancer at different stages of the disease. Information on age, menstrual status, BMI and tumor characteristics were recorded. Serum 25-hydroxy vitamin D concentrations were measured by radioimmunoassay (RIA). Mean and standard deviation were used to describe the data. Meanwhile, T-test and sum of squares test were used to analyze the data. P<0.05 was considered significant.

Results: Among 200 patients, 47 (23.5%) had severe vitamin D deficiency, 75 (37.5 %) had mild vitamin D deficiency and 78 (39.0 %) had sufficient vitamin D levels. There was a significant correlation between low vitamin D levels and advanced stage of breast cancer, particularly in postmenopausal patients.

Conclusion: It seems that lower levels of vitamin D accompany worse clinicopathologic features. Thus, treatment of vitamin D deficiency in postmenopausal patients might be of great benefits.

Keywords: Breast cancer, Vitamin D, Tumor stage, Menopausal status

INTRODUCTION

Vitamin D is a fat-soluble vitamin produced in the body.¹ Its main function is increasing calcium absorption and contribution to bone mineralization. In recent years, epidemiologic and laboratory studies have implied that vitamin D deficiency has a role in the pathogenesis of breast cancer. In vitro studies have shown that 1, 25 (OH) vitamin D inhibits proliferation of breast cancer cells and makes them more differentiated;² also it seems to induce apoptosis.³ Experiments on animals have shown that dietary vitamin D can inhibit carcinogenic effects of a high-fat diet on breast tissue. Moreover, 1, 25 (OH) vitamin D and its analogs can inhibit the growth of breast cancer cells and prevent tumor progression induced by...
carcinogens.\textsuperscript{4,5,6} Although 1, 25 (OH) vitamin D is the active vitamin D metabolite; its production is carefully tuned.\textsuperscript{7} Serum 25-OH vitamin D concentration is more correlated with the amount of vitamin D acquired from diet and sunlight exposure and it is a better indicator of the body vitamin D status.\textsuperscript{7-9} This study aimed to evaluate serum 25-hydroxyvitamin D level and its role in relation to tumor characteristics (local invasion, lymph node involvement, and metastasis) and menstrual status of the patients at Bagheban oncology clinic in Sari.

**SUBJECTS AND METHODS**

This was a cross-sectional study on 200 patients with breast cancer at different stages of the disease. After obtaining informed consent from the subjects, a questionnaire including information on age, parity, menstrual status (pre-menopause, menopause), BMI, and tumor characteristics was completed for each patient. The following factors were considered as exclusion criteria: hepatic or renal failure, metabolic bone disease, malabsorption and recent consumption of vitamin D (patients who had received oral vitamin D in recent two weeks, or vitamin D injection in recent 6 months). Blood samples were obtained from all patients. Serum 25-hydroxyvitamin D concentrations were measured using radioimmunoassay method (RIA) by a Japanese Hitachi analyzer and Elecsys casts. Serum calcium, phosphorus and alkaline phosphatase were measured by standard laboratory method, using Roche kits made in US and Cobas Integra 400 plus analyzer. Regarding the adequacy of vitamin D, the patients were classified into three groups: severe deficiency (<10 ng/ml), mild deficiency (10-25 ng/ml) and no evidence of deficiency (25-80 ng/ml).\textsuperscript{10}

Data were analyzed using the SPSS 16.0 software. Mean and standard deviation were used to describe the data. Meanwhile, T-test and sum of squares test were used to analyze the data. P-value less than 0.05 were considered statistically significant. Analysis of variance was used for comparison of more than two groups and analysis of covariance was employed for adjustment of any covariates. This work was approved by the local clinical research ethics committee (No: 92/3/8).

**RESULTS**

Mean concentration of serum vitamin D was 22.58 ± 14.21 ng/ml in 200 subjects, 47 patients (23.5 %) had severe vitamin D deficiency, 75 patients (37.5 %) had mild vitamin D deficiency and 78 patients (39.0 %) had sufficient vitamin D levels in serum. 40 patients (20%) had tumors with histologic grade 1, 128 patients (64 %) had grade 2 and 32 patients (16%) had grade 3 tumor. Evaluation of hormone receptors revealed that 144 (72%) patients were ER+ (estrogen receptor) and 127 (63.5 %) of whom were PR+ (progesterone receptor). Also, one hundred and forty-nine patients (74.5 %) were HER-2 + (human growth factor receptor 2). Lymph node involvement was observed in 111 patients (55.5%), and 20 patients (10%) had distant metastasis. Patients with distant metastases had significantly lower serum vitamin D levels compared to patients without distant metastasis (12.22 ± 2.28 ng/ml vs. 23.7 ± 1.06 ng/ml, respectively; P-value = 0.001). Serum vitamin D level in patients with lymph node involvement was lower than patients without lymph node involvement, but the difference was not statistically significant. (1.24 ± 20.91 ng/ml vs. 1.61 ± 24.65 ng/ml, P-value = 0.064). The comparison of vitamin D levels in patients with different number of involved lymph nodes, using analysis of variance, showed no significant difference among the 4 groups. (P-value= 0.098)(Figure 1).

Patients with higher tumor grade had lower levels of vitamin D compared to patients who had lower grade. This difference was significant by analysis of variance (P value < 0.0001) (Figure 2). A significant negative correlation was found between tumor size and levels of the vitamin D. Patients with greater size of tumor had lower level of the vitamin D (R = - 0.163, p-value = 0.021) (Figure 3). Vitamin D level was slightly different between hormone receptor-positive and hormone receptor-negative patients, but it was not statistically significant. Serum vitamin D level in premenopausal patients was less than postmenopausal ones (14.06 ± 21.54 ng/ml vs. 14.35 ± 23.69 ng/ml) and this difference was not statistically significant (P-value = 0.285). Vitamin D level and its association with histologic and
prognostic features of breast tumors were also evaluated and compared in premenopausal and postmenopausal patients. The relationship between vitamin D level and disease stage in the two groups (before and after menopause) is shown in Table 1. Vitamin D levels show no significant difference in premenopausal and postmenopausal patients regarding hormonal receptor and HER2 status (Table 2). The relationship between vitamin D levels and lymph node involvement and also stage of the disease in patients before and after menopause are shown in Table 3 and Table 4, respectively. A significant relationship was observed between low levels of vitamin D and stage of the disease and lymph node involvement only in the postmenopausal patients. After conducting a multivariate analysis, it was revealed that the difference between levels of vitamin D in the patients with early and advanced stages of breast cancer still remained statistically significant (Table 5).

**DISCUSSION**

The protective effect of vitamin D against breast tumor progression was introduced first time by Garland in 1980\(^2\) during the following years many studies have demonstrated this association.\(^{15,16,23,24}\) In recent years, researchers have focused on the relationship between vitamin D levels and breast cancer prognostic factors such as tumor size, histologic grade and stage of the disease, lymph node involvement, hormone receptor status and metastasis. Different studies have found different and sometimes contradictory results.\(^{20,21,25}\) In this study, serum vitamin D levels in 200 patients at different stages of breast cancer was evaluated. The mean serum 25-hydroxyvitamin D level was 22.58 ± 14.21 ng/ml. Vitamin D level was normal in 39% of patients, while 37.5% and 23.5% had mild and severe deficiency, respectively. The results of the study in Iran and the Middle East revealed that the incidence of vitamin D deficiency was between 30% - 80%, compatible with our findings.\(^{11-14}\) In the present study, serum 25-hydroxyvitamin D level had a significant inverse association with metastatic breast cancer. Low levels of vitamin D were also significantly associated with advanced stages of the disease, tumor size and grade, while no significant correlation was observed between serum 25-(OH) vitamin D and lymph node involvement or hormone receptor status. Of 200 patients, 96 (48%) were postmenopausal and 104 (52%) were premenopausal.

| Menopausal status | Disease stage | Mean vitamin D level (ng/ml) ± SD | p-value |
|-------------------|---------------|----------------------------------|---------|
| Premenopause      | Early         | 22.983 ± 14.8852                 | 0.093   |
|                   | Advanced      | 17.819 ± 11.0729                 |         |
| Postmenopause     | Early         | 26.473 ± 14.2326                 | 0.007   |
|                   | Advanced      | 18.144 ± 13.1192                 |         |

| Menopausal status | Hormonal receptor status | Mean vitamin D level (ng/ml) ± SD | p-value |
|-------------------|--------------------------|----------------------------------|---------|
| Premenopause      | Estrogen receptor negative | 19.70 ± 10.580                   | 0.421   |
|                   | Estrogen receptor positive | 22.22 ± 15.159                   |         |
|                   | Progesterone receptor negative | 20.63 ± 9.933                   | 0.653   |
|                   | Progesterone receptor positive | 21.97 ± 15.670                   |         |
|                   | HER2 negative             | 19.85 ± 13.574                   | 0.449   |
|                   | HER2 positive             | 22.20 ± 14.291                   |         |
| Postmenopause     | Estrogen receptor negative | 21.48 ± 13.454                   | 0.410   |
|                   | Estrogen receptor positive | 24.48 ± 14.736                   |         |
|                   | Progesterone receptor negative | 23.46 ± 14.799                   | 0.89    |
|                   | Progesterone receptor positive | 23.87 ± 14.163                   |         |
|                   | HER2 negative             | 23.90 ± 19.083                   | 0.940   |
|                   | HER2 positive             | 23.64 ± 12.783                   |         |
Serum vitamin D levels were not significantly different between the two groups. Tumor characteristics and their relation to vitamin D levels were evaluated separately in two groups of patients (pre- and post-menopause). A significant relationship was observed between low levels of vitamin D, stage of the disease and tumor size.
Metastasis was only found in postmenopausal patients, but in premenopausal patients there was no significant association. Hence, our results indicate a significant relationship between low vitamin D levels and advanced stages of breast cancer in menopausal patients. The study of Palmieri et al.\textsuperscript{15} also showed that vitamin D levels in metastatic and advanced stages of breast cancer were significantly lower than early stages of the disease. However, based on study of Asvadi et al.\textsuperscript{16} only P53 gene alteration was associated with low vitamin D levels among the prognostic features of breast tumors. Tumor size, tumor grade, lymph node involvement, disease stage and hormone receptor status were not associated with vitamin D levels. Larsson et al.\textsuperscript{17} reported a relationship between low levels of vitamin D and negative hormone receptors (ER- and PR-), but no relationship was reported between low levels of vitamin D and other features of tumor. The study of Hatse et al.\textsuperscript{18} also showed lower levels of vitamin D in patients with breast cancer compared to healthy controls.

The survey also revealed that only tumor size among the prognostic features of tumor had a significant correlation with lower levels of vitamin D and other tumor characteristics including tumor grade, receptor status and disease stage were not significantly associated with vitamin D level. A three-year follow-up study showed that higher levels of vitamin D had a significant relationship with improved overall survival, especially in breast cancer.

In a study in South Korea, a significant association was found between low levels of vitamin D and poor outcome in breast cancer and triple negative tumors.\textsuperscript{15} The study of Peppon et al.\textsuperscript{20} has shown a relationship between low serum levels of vitamin D and increased risk of estrogen- receptor negative (ER-) breast cancer. By contrast, the study conducted by Imtiaz et al.\textsuperscript{21} showed no relationship between serum vitamin D levels and tumor prognostic features. The fundamental importance of vitamin D is shown in regulating cell behaviors such as cell growth in in vitro studies of breast cancer cells as well as in vivo animal experiments\textsuperscript{6,26} as the ability of 1, 25 (OH) vitamin D in inhibiting proliferation and promoting differentiation and apoptosis.\textsuperscript{27-30}

In addition, a descriptive study indicated lower levels of 1, 25 (OH) vitamin D in women with a primary diagnosis of breast cancer compared to healthy controls.\textsuperscript{31} The study also revealed a decreased serum vitamin D levels in patients with metastatic cancer of bone in comparison with early stages of the disease.\textsuperscript{32} It is not clear exactly why 25-hydroxy vitamin D levels in patients with advanced breast cancer are lower than those of early stages.
It is also not clearly identified in the research that low levels of vitamin D are the causes of the advanced stages of cancer or direct results of advanced disease such as reduced food intake due to cancer or impaired vitamin D synthesis in the skin. 24 hydroxylase, an enzyme that inactivate 1, 25 hydroxy vitamin D and plays a role in homeostasis of its serum level, appears to be oncogene.\textsuperscript{33} It has been shown that the incidence of 24- hydroxylase in primary tumors of breast is higher than normal breast tissue, and the level of 1, 24 and 25- hydroxyvitamin D is significantly higher in malignant breast tumors; but it does not cause anti-proliferative response in breast cancer cells. In vitro studies have shown that the effect of this enzyme can be reversible by antisense inhibition. Therefore, theoretically, there can be a potential mechanism for resistance to the effects of vitamin D on breast tumors (by dysregulation of 24-hydroxylase activity). However, it is not clear that how this mechanism is different in early and advanced stages of cancer.\textsuperscript{34} It is possible that higher dysregulation of vitamin D metabolism at the advanced stages of breast cancer leads to some paracrine effects of tumor; or tumors with high levels of 24-hydroxylase may be at higher risk of more advanced stages. On the other hand, microarray analysis revealed the existence of several key genes which are up- and down-regulated by vitamin D therapy. Cyclin-dependent kinase inhibitor P21 is one of the key genes that is upregulated due to treatment with vitamin D and has an important role in controlling the cell cycle.\textsuperscript{35} Thus; it appears that changes in serum levels of vitamin D could potentially result in significant effects on gene transcription and thus, on cell phenotype.

CONCLUSION

According to our results, it seems that lower levels of vitamin D are associated with worse clinicopathologic features. Thus, treatment of vitamin D deficiency in post-menopausal patients may be of great consequence. We suggest further studies on genetic regulation of vitamin D metabolism in breast cancer patients.

ACKNOWLEDGEMENT

This study was performed in Andisheh laboratory, Sari, Iran and we thank Doctor Mohammadzadeh.

CONFLICT OF INTEREST

None declared.

REFERENCES

1. Heaney RP, Dowell MS, Hale CA, et al. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr. Apr 2003; 22(2):142-6.

2. Frappart L, Falette N, Lefebvre MF, et al. In vitro study of effects of 1, 25-dihydroxyvitamin D3 on the morphology of human breast cancer cell line BT20. Differentiation. 1989; 40:63–9.

3. James SY, Mackay AG, Colston KW. Effects of 1, 25 dihydroxy vitamin D3 and its analogues on induction of apoptosis in breast cancer cells. J Steroid Biochem Mol Biol. 1996; 58:395–401.

4. Jacobson E, James K, Newmark H, et al. Effects of dietary fat, calcium and vitamin D on growth and mammary tumorigenesis induced by 7, 12-dimethylbenz(a)anthracene in female Sprague-Dawley rats. Cancer Res. 1989; 49:6300–3.

5. Colston KW, Chander SK, Mackay AG, et al. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol. 1992; 44:693–702.

6. Anzano MA, Smith JM, Uskokovic MR, et al. 1a-Dihydroxy-16-ene-23-yn-26,27 hexafluorocholecalciferol (Ro24–5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. Cancer Res. 1994; 54:1653–6.

7. Reichel H, Koefflner HP, Norman AW. The role of the vitamin D endocrine system in health and disease. N Engl J Med. 1989; 320: 980 – 91.

8. Webb AR, Pilbeam C, Hanafin N, et al. An evaluation of the relative contributions of exposure to sunlight and of diet to the circulating concentrations or 25-hydroxyvitamin D in an elderly nursing home population in Boston. Am J Clin Nutr. 1990; 51:1075 – 81.

9. Salamone LM, Dallal GE, Zantos D, et al. Contributions of vitamin D intake and seasonal sunlight exposure to plasma 25-hydroxyvitamin D concentration in elderly women. Am J Clin Nutr. 1994; 59: 80 – 6.

10. Altundag MK, Icli F, Aksoy S, et al. Correlation of levels of serum 25-hydroxvitamin D and lymph node positivity in operable breast cancer: a Turkish oncology group. J Clin Oncol. 28:15s, 2010 (suppl; abstr 627).
11. Alagol F, Shihadeh Y, Boztepe H. Sunlight exposure and vitamin D in Turkish women. J Endocrinol Invest. 2000; 23: 173-7.
12. Niafar M, Bahrami A, Aliasgharzadeh A. Vitamin D status in healthy postmenopausal Iranian women. J Res Med Sci. 2009 May-Jun; 14(3): 171–177.
13. Dawoud A, Agarwal M, Hossain M. Hypervitaminosis D and vitamin D deficiency in exclusively breast feeding infants and their mother in summer: a justification for vitamin D supplementation of breast-feeding infants. J Pediatr. 2003; 142:169-73.
14. Hashemipour S, Larijani B, Adibi H, et al. Vitamin D deficiency and causative factors in the population of Tehran. BMC Public Health. 2004; 4: 38.
15. Palmieri C, Mac Gregor T, Girgis S, et al. Serum 25-hydroxyvitamin D levels in early and advanced breast cancer. J Clin Pathol. 2006; 59:1334–1336.
16. Asvadi Kermani I, Taghavi Kojidi H, Vaez Gharamaleki J, et al. Association of Serum Level of 25 Hydroxy-Vitamin D with Prognostic Factors for Breast Cancer. Asian Pacific J Cancer Prev. 2011; 12: 1381-1384.
17. Larsson SC, Bergkvist L, Wolk A. Long-term dietary calcium intake and breast cancer risk in a prospective cohort of women. Am J Clin Nutr. 2009; 89: 277-82.
18. Hatse S, Lambrechts D, Verstuy A, et al. Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency. Carcinogenesis. 2012; 33 (7):1319–1326.
19. Kim HJ, Lee YM, Ko BS, et al. Vitamin D deficiency is correlated with poor outcomes in patients with luminal type breast cancer. Ann Surg Oncol. 2011; 18:1830-6.
20. Peppone LJ, Rickles AS, Janelins MC, et al. The association between breast cancer prognostic indicators and serum 25-OH vitamin D levels. Ann Surg Oncol. 2012; 19(8):2590-9.
21. Imtiaz S, Siddiqui N, Raza SA, et al. Vitamin D deficiency in newly diagnosed breast cancer patients. Indian J Endocr Metab. 2012;16:409-13.
22. Garland CF, Garland FC, Gorham ED, et al. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med. 1990; 19:614–22.
23. Lin J, Manson JE, Lee IM, et al. Intakes of calcium and vitamin D and breast cancer risk in women. Arch Intern Med. 2007; 167: 1050–9.
24. Rossi M, Mc Laughlin JK, Lagiou P, et al. Vitamin D intake and breast cancer risk: a case-control study in Italy. Ann Oncol. 2009; 20: 374-8.
25. Abbas S, Chang-Claude J, Linseisen J. Plasma 25-hydroxy vitamin D and premenopausal breast cancer risk in a German case-control study. Int J Cancer. 2009; 124: 250–255.
26. Van Weelden K, Flanagan L, Binderup L, et al. Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog EB1089. Endocrinology. 1998; 139:2102–10.
27. Chouvet C, Vicard E, Devonee M, et al. 25-Dihydroxyvitamin D3 inhibitory effect on growth of two human breast cancer cell lines (MCF-7, BT-20). J Steroid Biochem. 1986;24: 373–6.
28. Frappart L, Falette N, Lefebvre MF, et al. In vitro study of effects of 1,25-dihydroxyvitamin D3 on the morphology of human breast cancer cell line BT20. Differentiation. 1989; 40:63–9.
29. James SY, Mackay AG, Colston KW. Effects of 1, 25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells. J Steroid Biochem Mol Biol. 1996; 58:395–401.
30. Jacobson E, James K, Newmark H, et al. Effects of dietary fat, calcium, and vitamin D on growth and mammary tumorigenesis induced by 7, 12-dimethylbenz(a)anthracene in female Sprague-Dawley rats. Cancer Res. 1989; 49:6300–3.
31. Janowsky EC, Lester GE, Weinberg CR, et al. Association between low levels of 1, 25-dihydroxyvitamin D and breast cancer risk. Public Health Nutr. 1999; 2: 283–91.
32. Mawer EB, Walls J, Howell A, et al. Serum 1, 25-dihydroxyvitamin D may be related inversely to disease activity in breast cancer patients with bone metastases. J Clin Endocrinol Metab. 1997; 82:118–22.
33. Albertson DG, Ylstra B, Seagraves R, et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet. 2000; 25:144–6.
34. Townsend K, Banwell CM, Guy M, et al. Autocrine metabolism of vitamin D in normal and malignant breast tissue. Clin Cancer Res. 2005; 11:3579–86.
35. Swami S, Raghavachari N, Muller UR, et al. Vitamin D growth inhibition of breast cancer cells gene expression patterns assessed by cDNA microarray. Breast Cancer Res Treat. 2003; 80:49–62.